Subsequently, the agents were evaluated as a second or later-line treatment in a phase II (NCT02150967) study that included patients (n = 71) diagnosed with advanced iCCA harboring FGFR2 fusions. Here, FGFR2 is linked to infantile convulsions and choreoathetosis.